Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Osteoarthritis and Cartilage Open

Genetically informed search for potential osteoarthritis drug targets across the proteome

8 affiliations
  1. 1Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
  2. 2Centre for Rheumatic Diseases, King's College London, London, UK
  3. 3Faculty of Medicine, KU Leuven, Leuven, Belgium
  4. 4Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
  5. 5Centre for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
  6. 6Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
  7. 7NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK
  8. 8Department of Medicine, Harvard Medical School, Boston, MA, USA

Abstract

Objective: Osteoarthritis (OA) is a leading cause of disability, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential disease-modifying OA drug (DMOAD) targets by integrating genetic and differential protein abundance (DPA) evidence.

Method: We evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three European cohorts (UK Biobank Pharma Proteomics Project, deCODE, and Fenland) and outcome data from the Genetics of Osteoarthritis Consortium across 11 OA phenotypes. Following limit-of-detection and missingness filtering, DPA evaluated 2133 proteins in 7186 prevalent OA cases and 29,584 controls from UK Biobank. MR-prioritised proteins were further assessed using summary-data-based Mendelian randomisation (SMR) with OA joint-tissue eQTL data, alongside pathway, protein-interaction, and druggability analyses.

Results: Cis-MR and colocalisation prioritised 81 proteins, of which 30 showed joint-tissue transcriptomic support in SMR analyses. DPA identified 1436 proteins associated with ≥1 OA phenotype, of which 1314 (91.5%) retained significance in sensitivity analyses. Seventeen proteins had matched MR and DPA support, including three Tier 1 druggable targets (DLK1, SOST, and TNFRSF9); seven of these had SMR support. EHBP1, LGALS3, and OGN showed concordant DPA and MR effects and cross-platform evidence. EHBP1, PCSK7 and ITIH4 emerged as under-recognised candidates. Pathway analyses recapitulated established OA processes, while drug enrichment identified hypothesis-generating compounds.

Conclusion: Integration of cis-MR, colocalisation, DPA, and tissue-specific transcriptomic evidence prioritised several potential OA therapeutic targets. DLK1, LGALS3, OGN and EHBP1 emerged as high-priority candidates, while EHBP1, PCSK7 and ITIH4 represent under-recognised candidates warranting functional investigation.

Related

  1. Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization
    Zixuan Wang, Dexin Wang, Longke Ran +2
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Genetically informed therapy for valvular heart disease: what, where, and when to target
    Yuze Mi, Yanggang Hong
    eBioMedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefPMC
  3. A genetically informed investigation into the relationship between childhood maltreatment and adult health
    Solveig Løkhammer, Eleni Friligkou, Dora Koller +4
    Translational PsychiatryPeer-reviewedCC BY-NC-ND 4.0Full textPsychiatry & mental healthCrossref
  4. Thermal proteome profiling identifies new drug targets in Plasmodium falciparum parasites
    Samuel Pazicky, Jerzy M. Dziekan, Seth Tjia +4
    Molecular & Cellular ProteomicsPeer-reviewedCC BY-NC-ND 4.0Full text2 citedEpidemiology & public healthCrossrefPMC
  5. Microcystin-LR exposure induces cartilage degeneration and dysregulates osteoarthritis-associated targets: an integrative computational and experimental study
    Zhifang Tang, Zuyong Feng, Zhiyu Liang +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMCEurope PMC
BibTeX
@article{liu2026genetically,
  title = {{Genetically informed search for potential osteoarthritis drug targets across the proteome}},
  author = {Weijie Liu and Benjamin P. Zuckerman and Art Schuermans and Gisela Orozco and Michael C. Honigberg and John Bowes and Terence W. O'Neill and Sizheng Steven Zhao},
  journal = {Osteoarthritis and Cartilage Open},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ocarto.2026.100890},
  url = {https://doi.org/10.1016/j.ocarto.2026.100890},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Genetically informed search for potential osteoarthritis drug targets across the proteome
AU  - Weijie Liu
AU  - Benjamin P. Zuckerman
AU  - Art Schuermans
AU  - Gisela Orozco
AU  - Michael C. Honigberg
AU  - John Bowes
AU  - Terence W. O'Neill
AU  - Sizheng Steven Zhao
PY  - 2026
DA  - 2026/10/24
JO  - Osteoarthritis and Cartilage Open
DO  - 10.1016/j.ocarto.2026.100890
UR  - https://doi.org/10.1016/j.ocarto.2026.100890
AB  - Objective: Osteoarthritis (OA) is a leading cause of disability, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential disease-modifying OA drug (DMOAD) targets by integrating genetic and differential protein abundance (DPA) evidence.  Method: We evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three European cohorts (UK Biobank Pharma Proteomics Project, deCODE, and Fenland) and outcome data from the Genetics of Osteoarthritis Consortium across 11 OA phenotypes. Following limit-of-detection and missingness filtering, DPA evaluated 2133 proteins in 7186 prevalent OA cases and 29,584 controls from UK Biobank. MR-prioritised proteins were further assessed using summary-data-based Mendelian randomisation (SMR) with OA joint-tissue eQTL data, alongside pathway, protein-interaction, and druggability analyses.  Results: Cis-MR and colocalisation prioritised 81 proteins, of which 30 showed joint-tissue transcriptomic support in SMR analyses. DPA identified 1436 proteins associated with ≥1 OA phenotype, of which 1314 (91.5%) retained significance in sensitivity analyses. Seventeen proteins had matched MR and DPA support, including three Tier 1 druggable targets (DLK1, SOST, and TNFRSF9); seven of these had SMR support. EHBP1, LGALS3, and OGN showed concordant DPA and MR effects and cross-platform evidence. EHBP1, PCSK7 and ITIH4 emerged as under-recognised candidates. Pathway analyses recapitulated established OA processes, while drug enrichment identified hypothesis-generating compounds.  Conclusion: Integration of cis-MR, colocalisation, DPA, and tissue-specific transcriptomic evidence prioritised several potential OA therapeutic targets. DLK1, LGALS3, OGN and EHBP1 emerged as high-priority candidates, while EHBP1, PCSK7 and ITIH4 represent under-recognised candidates warranting functional investigation.
SN  - 2665-9131
ER  -